A Randomized, Double-blind, Placebo-controlled Study to Assess QTc Interval Prolongation of Standard Dose Aflibercept in Cancer Patients Treated With Docetaxel
Pierre Maison‐Blanche(Inserm), E. Magherini(Sanofi (France)), Eyal Meiri(Palm Beach Neurology), Troy H. Guthrie(Baptist Cancer Center), Dana Grecea(Institute of Oncology Prof. Dr. Ion Chiricuta), Stefano Cascinu(Vita-Salute San Raffaele University), Sylvie Rottey(Ghent University Hospital), Emmanuelle Boëlle(Sanofi (France)), Gedske Daugaard(Copenhagen University Hospital), Elke Jäger(Krankenhaus Nordwest), Alexandru Eniu(Institute of Oncology Prof. Dr. Ion Chiricuta), Sanjiv S. Agarwala(Goethe University Frankfurt), Tuncay Göksel(Heidelberg University), Constantin Volovăț(Institutul Regional de Oncologie), Gökhan Demir(Cliniques Universitaires Saint-Luc), Lisa Sengeløv(St Bartholomew's Hospital), Mario Nardi(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), M. E. Scheulen, Michael Clemens(Klinikum Mutterhaus der Borromäerinnen), Graziella Pinotti(Medica (Italy)), Jan B. Vermorken(University of Antwerp), Jean‐Pascal Machiels(Cliniques Universitaires Saint-Luc), Dirk Strumberg(Universitätsklinik Marien Hospital Herne)
Cited by 5
Related Papers
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer
|Journal of Clinical Oncology|2005|1.9k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k